Leerink Partners initiated coverage of Satellos Bioscience with a rating of Outperform and set a new price target of $20.00

Cantor Fitzgerald initiated coverage of Satellos Bioscience with a rating of Overweight

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

S-8 - Satellos Bioscience Inc. (0001421642) (Filer)

40-F - Satellos Bioscience Inc. (0001421642) (Filer)

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) (" Satellos " or the " Company "), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada. Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference. 2026 Bloom Burton & Co. Healthcare Investor ConferenceFormat: Pres

Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker "MSLE" on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP, a placebo-controlled Phase 2 clinical trial of SAT-3247 in boys aged 7 to less than 10 years living with Duchenne muscular dystrophy ("Duchenne" or "DMD") Presented initial functional outcomes from 56 days of treatment in TRAILHEAD (follow-on trial to CL-101) at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, demonstrating that grip strength improvements observed in CL-101 were maintained or improved in TRAILHEAD over an aggregate period of 9 to 13 months Reported pro

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP studyProteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administrationPreclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247Enrollment ongoing in TRAILHEAD and BASECAMP

Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida. Oral presentations feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy

Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, Feb. 24, 2026, at 3:30 p.m. ET, featuring Kevin M. Flanigan, MD, the Wolfe Foundation Endowed Chair in Neuromuscular Research at Nationwide Children's Hospital and professor of pediatrics and neurology at The Ohio State University College of Medicine. Dr. Flanigan will join company management to discuss the unmet need and current treatment landscape for Duchenne muscular dystrophy (DMD). Interested participants may

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, today announced that management will present at and participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Format: Presentation Time: 10:40 a.m. – 11:10 a.m. ET Location: Virtual TD Cowen 46th Annual Health Care Conference Date: Tuesday, March 3, 2026 Format: Presentation Time: 1:10 – 1:40 p.m. ET Location: Boston, MA Leerink Partners Global Healthcare Conference Date: March 8-11, 2026

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 in NYC on Thursday, Feb. 12, 2026, at 10 a.m. ET. The fireside chat will be available via live webcast on the Events and Presentations page in the Investors section of the Company's website. A replay will be available following the event. Members of the Satellos leadership team will also be available for one-on-one investor meetings during the

Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it has completed its previously-announced underwritten public offering (the "Offering") of 5,168,019 common shares, which includes the exercise of the underwriters' option to purchase an additional 712,574 common shares and, in lieu of common shares for certain investors, pre-funded warrants to purchase 495,049 common shares. The common shares were sold at a price of US$10.10 per share (C$13.81 per common share) and the pre-funded warrants were sold at a price of US$10.09999 per